COO Cooper Companies Inc.

EssilorLuxottica and CooperCompanies Announce Joint Venture for Acquisition of SightGlass Vision

EssilorLuxottica and CooperCompanies Announce Joint Venture for Acquisition of SightGlass Vision

CHARENTON-LE-PONT, France, and SAN RAMON, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- EssilorLuxottica and CooperCompanies, two of the world’s leading vision care companies, have entered into an agreement to create a 50/50 joint venture for the acquisition of SightGlass Vision, a U.S. based life sciences company focused on developing innovative spectacle lenses to reduce the progression of myopia in children.

EssilorLuxottica and CooperCompanies will leverage their shared expertise and global leadership in myopia management to accelerate the commercialization of SightGlass Vision spectacle lenses. Through this partnership, they will further strengthen innovation opportunities and go-to-market capabilities to grow the myopia control category. SightGlass Vision’s technology will complement both companies’ existing solutions, including Essilor’s Stellest lens and CooperVision’s MiSight and Orthokeratology contact lenses. 

The last few decades have seen a steady rise in the prevalence of myopia across the globe, notably under the effect of lifestyle changes. Today affecting 2.6 billion people worldwide, it is estimated that nearly 5 billion people, or half of the world population, will be myopic by 2050. Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia. By combining their scientific expertise and product development capabilities, EssilorLuxottica and CooperCompanies intend to increase awareness and offer additional solutions to help address this global eye health issue.

We are excited to join forces with CooperCompanies, a company with a strong track-record in addressing major vision conditions, including myopia, and leverage together the SightGlass Vision technology. This partnership is fully consistent with EssilorLuxottica’s strategy to improve access to vision care, including solutions that can control myopia progression. The complementarity of our existing solutions, including Essilor’s recent Stellest lens, with SightGlass Vision’s promising technology will further strengthen our offer by providing advanced products answering to the growing needs of customers and consumers worldwide,” said Francesco Milleri and Paul du Saillant, respectively CEO and Deputy CEO of EssilorLuxottica.

EssilorLuxottica is a pioneer and global leader in the vision space and expanding our relationship to better tackle the rapidly growing myopia management marketplace is extremely exciting. By combining our strengths, we look forward to increasing the life-changing offerings available to global eye-care-practitioners to combat childhood myopia. This partnership is a natural extension to our existing portfolio of innovative myopia management products, including MiSight contact lenses, and we firmly believe this partnership will strengthen our ability to accelerate those offerings,” said Al White, CooperCompanies CEO and President.

The joint venture will acquire SightGlass Vision from CooperCompanies, and the closing of the acquisition and creation of the joint venture is subject to regulatory approvals and other customary closing conditions. CooperCompanies previously held a minority ownership interest in SightGlass Vision and completed its acquisition of SightGlass Vision in January 2021.

About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. Formed in 2018, its mission is to help people around the world to see more, be more and live life to its fullest by addressing their evolving vision needs and personal style aspirations. The Company brings together the complementary expertise of two industry pioneers, one in advanced lens technology and the other in the craftsmanship of iconic eyewear, to set new industry standards for vision care and the consumer experience around it. Influential eyewear brands including Ray-Ban and Oakley, lens technology brands including Varilux and Transitions, and world-class retail brands including Sunglass Hut and LensCrafters are part of the EssilorLuxottica family. For more information, please visit .

About CooperCompanies

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit .

Contacts: 
  
EssilorLuxottica CooperCompanies
Corporate Communications – Kim Duncan – VP, Investor Relations and Risk Management
Investor Relations –  925-460-3663 –

 



EN
03/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

Cooper Companies Inc: 1 director

Two Directors at Cooper Companies Inc bought 2,107 shares at between 0.000USD and 68.390USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...

 PRESS RELEASE

CooperCompanies Announces Expanded Share Repurchase Program

CooperCompanies Announces Expanded Share Repurchase Program SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share repurchase program now totals $2 billion. “We are pleased to announce that our Board of Directors has authorized an increase to our share repurchase program,” said Al White, President and Chief Executive Officer. “This decision underscores the strength of our balance sheet and cas...

 PRESS RELEASE

CooperCompanies Announces Third Quarter 2025 Results

CooperCompanies Announces Third Quarter 2025 Results SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 or 15% from last year's ...

 PRESS RELEASE

CooperCompanies to Participate in the Wells Fargo Healthcare Conferenc...

CooperCompanies to Participate in the Wells Fargo Healthcare Conference SAN RAMON, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025. Al White, President and CEO, will represent the Company in a session scheduled at 3:00 PM ET. The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at . About CooperCompaniesCooperCompanies (Nasdaq: COO) is a leading global me...

 PRESS RELEASE

CooperCompanies Announces Release Date for Third Quarter 2025

CooperCompanies Announces Release Date for Third Quarter 2025 SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at . About...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch